news

BHI Therapeutic Sciences Inc. Notified by FDA that is can proceed with New Drug Clinical Trial for Acute Ischemic Stroke

Posted by on Jun 5, 2018 in news | 0 comments

BHI Therapeutic Sciences (BHITS), a leader in stem cell therapy and research utilizing human umbilical cord blood, announced today that the company has been notified by the Food and Drug Administration (FDA) that its Investigational New Drug (IND) application to allow for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke may proceed.   Phase 1/2 Study entitled “Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects with Acute Ischemic Stroke” is a prospective, open-label, single-center,...

Read More

Professional Physique Champion is named Ambassador for BHI Slovakia.

Posted by on Jun 5, 2018 in news | 0 comments

Anton Antipov, an International Federation of Body Building and Fitness (IFBB) professional physique champion and fitness model, recently visited BHI Slovakia, stem cell research and treatment center, where he was named an ambassador for the healthcare organization. Mr. Antipov is an accomplished competitor and New York-based model, who has made a name for himself on social media and in the fitness industry. Growing up in Belarus, Mr. Antipov never had access to a gym, but he played sports to stay fit. After his family immigrated to America in the 1990s, Mr. Antipov had his first experience...

Read More

Stem Cells: The Next Frontier documentary screening for investors in NYC.

Posted by on Jun 5, 2018 in news | 0 comments

BHI Therapeutic Sciences (BHITS) and Brian Mehling, M.D. hosted a private screening of Stem Cells: The Next Frontier on Tuesday, February 13 in New York. The evening included a Q & A session and information on how to participate by becoming an investor to make these life-saving stem cells therapies more accessible to patients across the globe. “At BHITS, our philosophy is that stem cells are the future of medicine and we are excited to share our ideas with the general public and investors. BHITS is pioneering ethical, effective, safe and affordable stem cell treatment therapies...

Read More

BHI Therapeutic Sciences attended the World Economic Forum in Davos, Switzerland.

Posted by on Jun 5, 2018 in news | 0 comments

The 2018 World Economic Forum (WEF) in Davos explored the ideas, innovations and discoveries that are reshaping our world by working closely with those in the vanguard of change from such fields as the arts, culture, engineering, media, medicine, science, and technology. During the past few days, the US-based company BHI Therapeutic Sciences (BHITS) represented by Brian Mehling, MD, Founder and Chief Medical Officer; Klara Doert, President of International Business Development; Katarina Novakova, Director of Relations; and Manuel McDonald, International Consultant attended the annual meeting...

Read More

WORLD-RENOWNED STEM CELL RESEARCHER AND BOARD-CERTIFIED SURGEON, DR. BRIAN MEHLING, SET TO ATTEND THE 48TH ANNUAL WORLD ECONOMIC FORUM IN DAVOS

Posted by on Jun 5, 2018 in news | 0 comments

FOUNDER OF BLUE HORIZON INTERNATIONAL AVAILABLE TO DISCUSS BREAKTHROUGHS IN STEM CELL RESEARCH   ZURICH, Switzerland – January 18, 2017 – Dr. Brian Mehling, world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, and founder of Blue Horizon International (BHI), will be attending The 48th Annual World Economic Forum (WEF) in DAVOS from January 23-26. This will be Dr. Mehling’s sixth year attending the global conference.   The theme of this year’s forum is “Creating a Shared Future in a Fractured World” and discussions will centralize around how...

Read More

Brian Mehling, M.D. and Blue Horizon International team to attend 3 Day Masterclass in Clinical Trials in New York

Posted by on Jun 27, 2017 in news | 0 comments

The 3 day long Masterclass in Clinical Trials and Medicine Development is organized by Terrapinn Ltd and will be held during February 22 – 24, 2017 in New York, NY.   The Masterclass in Clinical Trials is designed to provide insight into new business opportunities in the field of clinical trials and the development process of new healthcare interventions. The course will provide insight into complex cross-disciplinary integrated health within the process of diffusion of new medical interventions, from pharmaceuticals, medical devices, diagnostics, surgical interventions to dietary...

Read More